Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555081 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
NCT06555081 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 168 participants.
The verdict
NCT06555081, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
Study Summary
This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
Interventions
- DRUG Ruxolitinib IR
- DRUG Ruxolitinib XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06555081
The ClinicalTrials.gov registry entry for NCT06555081 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib IR is the first listed.
NCT06555081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06555081 about?
NCT06555081 is a clinical study titled "A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants". This study is conducted to determine the Bioequivalence of Ruxolitinib XR 55 mg Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
What is the current status of trial NCT06555081?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2024-09-25. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT06555081?
The interventions under investigation include: Ruxolitinib IR (DRUG), Ruxolitinib XR (DRUG).
Who is sponsoring clinical trial NCT06555081?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.